Abstract: A battery accommodating module is used for accommodating a battery. The battery accommodating module includes a battery case and a latch member. The battery case has an accommodating space and a side of the battery case has two pivot holes and at least one first restraining portion. The latch member has two pivot portions and at least one second restraining portion, wherein the pivot portions are pivotally connected to the pivot holes, such that the latch member can rotate with respect to the battery case between a lock position and an unlock position. When the latch member is located at the unlock position, the first restraining portion keeps the second restraining portion at a first side of the first restraining portion. When the latch member is located at the lock position, the first restraining portion keeps the second restraining portion at a second side of the first restraining portion.

Abstract: A method and device for monitoring virus trend abnormality are provided which may enable timely and effective monitoring of computer viruses. The method may include measuring a frequency of hits of a virus being found and/or removed. The frequency may be used for calculating an M-day moving average value of the number of hits of the virus. Method may also involve calculating a standardized residual of the number of hits of the virus. When the standardized residual is larger than a first preset threshold, the time at which the virus was encounter the last may be identified as an abnormality point on a trendline of the virus.

Abstract: The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.

Abstract: A routing system may include a primary message group to be used for synchronizing stored information. The primary message group may include multiple primary network devices. The multiple primary network devices may be configured with a first configuration regarding synchronizing the stored information. The primary message group may form a ring network topology. The routing system may include a secondary message group to be used for synchronizing the stored information. The secondary message group may include a single primary network device, of the multiple primary network devices, and multiple secondary network devices. Each secondary network device, of the multiple secondary network devices, may be included in a single secondary message group. The multiple secondary network devices may be configured with a second configuration regarding synchronizing the stored information. The secondary message group may form a different ring network topology.

Abstract: Liposome-based mucus-penetrating particles (MPP) capable of loading hydrophilic agents including therapeutic, prophylactic and diagnostic agents such as the diaCEST MRI contrast agent barbituric acid (BA) were evaluated to determine how to optimize delivery. Polyethylene glycol (PEG)-coated liposomes containing ?7 mol % PEG diffused only approximately 10-fold slower in human cervicovaginal mucus (CVM) compared to their theoretical speeds in water. 7 mol %-PEG liposomes provided improved vaginal distribution compared to 0 and 3 mol %-PEG liposomes.

Abstract: A method and apparatus for managing remote devices. In one embodiment of the present invention, there is provided a method of managing a remote device, comprising: obtaining a first identifier based on a name sequence in state information of the remote device, the first identifier being for indicating a template that provides the state information; obtaining a second identifier based on a numerical value sequence in the state information; sending a state access notification that comprises at least the first identifier and the second identifier; and providing the state information based on the first identifier and the second identifier in response to having received a result of activating the state access notification. In one embodiment of the present invention, there is provided an apparatus for managing a remote device.

Abstract: Aspects of the embodiments are directed to passive depth determination. Initially, a high power depth map of a scene can be created. An object in the scene can be identified, such as a rigid body or other object or portion of an object. A series of lower power or RGB images can be captured. The object can be located in one or more of the lower power or RGB images. A change in the position of an object, represented by a set of pixels, can be determined. From the change in position of the object, a new depth of the object can be extrapolated. The extrapolated depth of the object can be used to update the high power depth map.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: The present disclosure provides computer-implemented systems and processes for clustering items and improving the utility of item recommendations. One process involves applying a clustering algorithm to users' search session queries over periods of time to generate query clusters comprising correlated query terms. Correlations may be based on, among other things, the frequency of which query term pairs appear together in a single search session. The generated query clusters may be used to generate item descriptor clusters indicative of items and/or types of items that may be complementary. Other criteria may be applied to the query and item clusters to generate variant clusters. For example, information such as related brands, market segments, and other data may be applied to item descriptor clusters to generate item clusters that include complementary items associated with or targeted for particular demographics. Item descriptor clusters and item clusters can be used to improve the item recommendations.

Abstract: The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.

Abstract: The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R1, R2 and R11 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Abstract: An electronic module includes a base, a carrying structure, an electronic component and a cable. The carrying structure includes a carrying portion and a cable arranging portion. The carrying portion is slidably disposed in the base, the cable arranging portion is connected to the carrying portion, and at least a part of the cable arranging portion is adapted to be bent. The electronic component is carried on the carrying portion. The cable is connected between the electronic component and the base and is position-limited by the cable arranging portion. When the carrying portion at least partially slides out of the base, the cable is deformed with the cable arranging portion. In addition, an electronic apparatus having the electronic module is also provided.

Abstract: The present invention relates to Fused Tricyclic Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocyclic Compound, and methods of using the Fused Tricyclic Heterocyclic Compounds for treating or preventing HIV infection in a subject.

Abstract: A payload monitoring system on a machine includes a payload sensor configured to generate a plurality of payload data corresponding to a payload amount in a bucket of a machine, the plurality including a first payload data and a second payload data and a controller. The controller is configured to receive the first payload data from the payload sensor and off-board payload data from an off-board system, compare the first payload data to the off-board payload data to generate a payload data offset, receive the second payload data from the payload sensor, and generate an adjusted payload data based on the second payload data and the payload data offset.

Abstract: A payload monitoring system on a machine includes a payload sensor configured to generate a plurality of payload data corresponding to a payload amount in a bucket of a machine, the plurality including a first payload data and a second payload data and a controller. The controller is configured to receive the first payload data from the payload sensor and off-board payload data from an off-board system, compare the first payload data to the off-board payload data to generate a payload data offset, receive the second payload data from the payload sensor, and generate an adjusted payload data based on the second payload data and the payload data offset.

Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

Abstract: A chemically prepared toner composition according to one example embodiment includes a core including a first polymer binder, a second polymer binder, a colorant and a release agent; a shell that is formed around the core and includes a third polymer binder; and a borax coupling agent between the core and the shell. The first and third polymer binders are different amorphous polyester resins. The second polymer binder is a crystalline polyester resin and acts as a plasticizing agent in the core. The borax coupling agent assists in adhering the shell to the outer surface of the core. Optionally, the toner of the present invention may be finished with a set of extra particulate additives.

Abstract: Disclosed is a pyridino[1,2-a]pyrimidone analogue used as a PI3K inhibitor. The present invention particularly relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a light field illuminating method, device and system. The method includes: determining, based on position and angle of rays emitted from a projector and focal length of a lens, position and angle of projection rays obtained after the emitted rays being transmitted through a lens array; determining, based on position and angle of projection rays and light probe array of sampled scene, brightness value of projection rays; converting, based on brightness transfer function of projector, brightness value of projection rays into pixel value of projection input image, generating projection input image based on pixel value of projected input image; and performing light field illumination on target object with projection input image. A projector and a lens array are adopted to achieve light field illumination, so that pixel-level accurate lighting control can be achieved, and various complicated light field environments can be simulated vividly in practical scenario.